Showing 871-880 of 10182 results for "".
Sunscreen Water Seems All Washed Up; Fake Cosmeceuticals Raise Concerns
https://practicaldermatology.com/series/dermwire-tv/dermwiretv-sunscreen-water-seems-all-washed-up-fake-cosmeceuticals-raise-concerns/19119/In this edition of DermWireTV, from the publishers of Practical Dermatology® magazine we take a look at drinkable sunscreen and school bans on sunscreens, get an update on Vegas Cosmetic Surgery, and meet the new face of AMBI skincare. Plus, our DermFocus investigates the problem of counterfeit cosSINON by Quantel Derma
https://practicaldermatology.com/topics/aesthetics-cosmeceuticals/sinon-by-quantel-derma/19387/The ruby laser system with active Q-switch against natural pigmentations and tattoos. The Q-switched ruby laser system SINON has a wavelength of 694 nm. It applies ultra short pulses of only 20 ns for effective treatments even with low fluency. Thus, SINON is fast, reliable and gentle and able to rPart 3, 1726 nm lasers: How to talk to patients about incorporating the 1726 nm wavelength lasers into their treatment regimens: Hint is to be patient
https://practicaldermatology.com/series/scientifically-speaking/1726-nm-lasers-five-dermatologists-discuss-the-lasers-benefits-and-drawbacks-for-treating-acne-and-other-skin-conditions/24341/Chapter 3 of 7: David Goldberg, MD, from New York, Emil Tanghetti, MD, from Sacramento, Jordan Wang, MD, from Philadelphia and New York and Naz Saedi, MD, from Philadelphia talk about how to talk to patients about incorporating the 1726 nm wavelength lasers into their treatment regimens: Hint is toDWTV Extra: Image-Guided SRT Consensus
https://practicaldermatology.com/series/dermwire-tv/dwtv-extra-image-guided-srt-consensus/35744/Jacob Scott, MD, chairman of the Dermatology Association of Radiation Therapy (DART), discusses an expert panel's recommendations on the role of image-guided superficial radiation therapy in the treatment of non melanoma skin cancer, which were published in an article titled "The Role of Image-GuidePart 4, 1726 nm lasers: Handling referred patients who are already on different treatment regimens
https://practicaldermatology.com/series/scientifically-speaking/1726-nm-lasers-five-dermatologists-discuss-the-lasers-benefits-and-drawbacks-for-treating-acne-and-other-skin-conditions/24342/Chapter 4 of 7: David Goldberg, MD, from New York, Emil Tanghetti, MD, from Sacramento, Jordan Wang, MD, from Philadelphia and New York and Naz Saedi, MD, from Philadelphia talk about handling referred patients who are already on different treatment regimens.June Issue: Melanoma Updates - Epidemiology, Diagnostics, and Treatment
https://practicaldermatology.com/issues/may-june-2025/melanoma-updates-epidemiology-diagnostics-and-treatment/35917/In this article, we review the latest changes in melanoma incidence and mortality, highlight key disparities among minority populations, and summarize emerging trends in technology and treatment that are reshaping the future of melanoma care.Calling Out Hesitation on Systemics
https://practicaldermatology.com/programs/practical-dermatology/calling-out-hesitation-on-systemics/35703/The latest news and updates, plus Jason E. Hawkes, MD, MS, FAAD, joins Practical Dermatology Chief Medical Editor Neal Bhatia, MD, FAAD, to discuss why dermatologists should not be reluctant to prescribe systemic therapies, and Linda F. Stein Gold, MD, discusses the importance of an ever-expanding aStudy Examines Association Between Childhood BMI and Risk of Developing IMSDs
https://practicaldermatology.com/series/dermwire-tv/study-examines-association-between-childhood-bmi-and-risk-of-developing-imsds/27004/In this week's DermwireTV, a new study examines the relationship between childhood BMI and skin diseases; phase 3 data sheds new light on dupilumab’s effect on inflammatory biomarkers in pediatric AD patients; and the president and CEO of Evolus discusses trends in the injectables market.The Impact of Clascoterone Topical Cream, 1%: The US Experience 4 Years After Approval and Clinical Expectations for Acne Patients in Other Regions of the World
https://practicaldermatology.com/topics/acne-rosacea/Impact-Clascoterone-Topical-Cream/32830/Clascoterone topical cream, 1% (Winlevi), approved by the US Food and Drug Administration (FDA) in 2020 as the first novel drug introduced for the treatment of acne vulgaris since 1982, is indicated in the US for patients 12 years of age and older. The safety and efficacy were supported by two succeScience of Skincare Summit 2024: On the FDA Approval of Emrosi for Rosacea
https://practicaldermatology.com/conferences/science-skincare-summit-2024/science-of-skincare-summit-2024-on-the-fda-approval-of-emrosi-for-rosacea/29276/At the Science of Skincare Summit in Austin, Practical Dermatology caught up with Chief Medical Editor Neal Bhatia, MD, and James Del Rosso, DO, a dermatologist and Editor in Chief of Clinical Dermatology at the Journal of Clinical and Aesthetic Dermatology (JCAD), who shared insights and thoughts o